SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that researchers at the King Faisal Specialist Hospital and Research Centre (KFSH&RC) in the Kingdom of Saudi Arabia and University Medical Center Hamburg (UMCH) have used Affymetrix microarray technology to discover a gene amplification associated with breast disease and breast cancer. The study, “Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer,” was published in a recent issue of Nature Genetics.
